teriflunomide / Generic mfg. 
Welcome,         Profile    Billing    Logout  

53 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
teriflunomide / Generic mfg.
2016-001515-20: nd nd

Ongoing
4
30
Europe
teriflunomide, nd, Film-coated tablet, AUBAGIO - 14 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) - 28 COMPRESSE
UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI, genzyme
RELAPSING-REMITTING MULTIPLE SCLEROSIS SCLEROSI MULTIPLA REMITTENTE RECIDIVANTE, ND ND, Diseases [C] - Nervous System Diseases [C10]
 
 
2016-003622-16: The effect of teriflunomide on brain microglial cell activation in multiple sclerosis.

Ongoing
4
30
Europe
Teriflunomide, L04AA31, Film-coated tablet, AUBAGIO
Turku University Hospital, Sanofi-aventis groupe
Multiple sclerosis, MS disease, Diseases [C] - Nervous System Diseases [C10]
 
 
2017-002634-24: MultipleMS – a study with the aim to accelerate personalised medicine in multiple sclerosis. MultipleMS - en studie med syftet att utveckla precisionsmedicin för multipel skleros.

Ongoing
4
150
Europe
Infusion, Capsule, Tablet, Injection, Mabthera, Tysabri, Tecfidera, Gilenya, Copaxone, Betaferon, Extavia, Avonex, Rebif, Plegridy, Lemtrada, Aubagio
Karolinska Institutet, Department of Clinical Neuroscience, Karolinska Institutet
Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive), Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS), characterized by repeated episodes of inflammation in the CNS leading to various neurological symptoms., Diseases [C] - Nervous System Diseases [C10]
 
 
2021-003195-13: Importance of monitoring of drugs used in the treatment of multiple sclerosis Význam terapeutického monitorování perorálně podávaných léčiv modifikující průběh choroby (“disease-modifying drugs”) užívaných k léčbě roztroušené sklerózy

Not yet recruiting
4
800
RoW
Aubagio 14MG TBL FLM, Mavenclad 10MG TBL NOB, Tecfidera 240MG CPS ETD, Gilenya 0,5MG CPS DUR, Tablet, Capsule, Aubagio 14MG TBL FLM, Mavenclad 10MG TBL NOB, Tecfidera 240MG CPS ETD, Gilenya 0,5MG CPS DUR
Fakultní nemocnice Ostrava, Fakultní nemocnice Ostrava
multiple sclerosis roztroušená skleróza, multiple sclerosis roztroušená skleróza, Diseases [C] - Nervous System Diseases [C10]
 
 
2021-002810-15: Peripheral neuropathy as potential side effect in patients with multiple sclerosis treated with teriflunomide.

Not yet recruiting
4
11
Europe
Coated tablet, AUBAGIO 14 mg
CHU Brugmann, CHU Brugmann
Multiple sclerosis, treated with teriflunomide, Multiple sclerosis, treated with teriflunomide, Diseases [C] - Nervous System Diseases [C10]
 
 
2022-004331-23: Monitoring of drugs used in the treatment of multiple sclerosis Sledování léčiv užívaných při léčbě roztroušené sklerózy

Not yet recruiting
4
150
RoW
Aubagio 14MG TBL FLM, Gilenya 0,5MG CPS DUR, Tablet, Capsule, hard, Aubagio 14MG TBL FLM, Gilenya 0,5MG CPS DUR
Fakultní nemocnice Ostrava, Fakultní nemocnice Ostrava
multiple sclerosis roztroušená skleróza, multiple sclerosis roztroušená skleróza, Diseases [C] - Nervous System Diseases [C10]
 
 
DELIVER-MS, NCT03535298: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Active, not recruiting
4
800
Europe, US
Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod)
The Cleveland Clinic, University of Nottingham
Multiple Sclerosis, Relapsing-Remitting
04/30
09/30
2018-001292-21: Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Arrêt des traitements de fond à visée immunologique chez les patients de plus de 50 ans ayant une sclérose en plaques secondairement progressive

Not yet recruiting
3
250
Europe
AVONEX, BETAFERON, EXTAVIA, REBIF, PLEDIGRY, COPAXONE, AUBAGIO, TECFIDERA, GILENYA, TYSABRI, IMUREL, NOVATREX, CELLCEPT, ENDOXAN, L03 AB 08, Concentrate for solution for injection, Powder for solution for injection, Solution for injection, Solution for injection in pre-filled syringe, Tablet, Capsule, Concentrate for solution for infusion
CHU de Rennes, CHU de Rennes
Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Diseases [C] - Nervous System Diseases [C10]
 
 
TERIS, NCT03122652: Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome

Completed
3
125
Europe, RoW
Teriflunomide 14 MG Oral Tablet [Aubagio], Placebo Oral Tablet
Centre Hospitalier Universitaire de Nice, Genzyme, a Sanofi Company
Multiple Sclerosis
02/19
10/22
TERIKIDS, NCT02201108 / 2011-005249-12: Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis

Active, not recruiting
3
166
Europe, Canada, US, RoW
Teriflunomide, AUBAGIO, HMR1726, Placebo
Genzyme, a Sanofi Company
Multiple Sclerosis
10/19
06/25
2015-002298-39: A national, multi-center study to evaluate the safety of long term treatment with teriflunomide 14 mg once daily in patients with a first clinical episode suggestive of multiple sclerosis in a long-term extension period.

Not yet recruiting
3
12
Europe
TERIFLUNOMIDE, HMR1726, Film-coated tablet, AUBAGIO
CHU de Nice, GENZYME
patient with Clinically isolated syndrome, multiple sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
2020-004505-32: Study of efficacy and tolerability of ofatumumab vs. First Line disease modifying treatment (DMT) - physician’s choice in the treatment of newly diagnosed relapsing multiple sclerosis (RMS) patients

Ongoing
3
236
Europe
ofatumumab, Glatiramer acetate, Interferon β-1b, Interferon β-1a, Peginterferon β-1a, Teriflunomide, Dimethyl fumarate, OMB157, Solution for injection in pre-filled pen, Solution for injection in pre-filled syringe, Powder and solution for solution for injection, Solution for injection, Solution for infusion in pre-filled syringe, Coated tablet, Gastro-resistant capsule, soft, Kesimpta
Novartis Pharma AG, Novartis Pharma AG
Multiple Sclerosis Sclérose en plaques, Multiple Sclerosis Sclérose en plaques, Diseases [C] - Nervous System Diseases [C10]
 
 
2020-005929-89: Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treatment with remibrutinib

Ongoing
3
800
Europe, RoW
remibrutinib, Teriflunomide, LOU064, Film-coated tablet, Capsule, hard + tablet, Aubagio
Novartis Pharma AG, NOVARTIS PHARMA AG, Novartis Farmacéutica S.A., Novartis Pharma AG
Multiple Sclerosis, Multiple Sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
2020-005899-36: Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treatment with remibrutinib Účinnosť a bezpečnosť remibrutinibu v porovnaní s teriflunomidom u pacientov s relabujúcou roztrúsenou sklerózou

Ongoing
3
800
Europe, RoW
remibrutinib, Teriflunomide, LOU064, Film-coated tablet, Capsule, hard + tablet, Aubagio
Novartis Pharma AG, NOVARTIS PHARMA AG, Novartis Farmacéutica S.A., Novartis Pharma AG
Multiple Sclerosis, Multiple Sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
MIRANTIBUS, NCT05385744: An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis

Recruiting
3
336
RoW
BCD-132, Teriflunomide
Biocad
Multiple Sclerosis
03/23
03/24
EVOLUTION RMS1, NCT04338022 / 2019-004972-20: Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

Terminated
3
1124
Europe, Canada, US, RoW
Evobrutinib, M2951, Placebo (match to Teriflunomide), Teriflunomide, Placebo (match to Evobrutinib)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, EMD Serono Research & Development Institute, Inc.
Relapsing Multiple Sclerosis
10/23
03/24
evolutionRMS 2, NCT04338061 / 2019-004980-36: Study of Evobrutinib in Participants With RMS

Terminated
3
1124
Europe, Canada, US, RoW
Evobrutinib, M2951, Placebo (match to Teriflunomide), Teriflunomide, Placebo (match to Evobrutinib)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, EMD Serono Research & Development Institute, Inc.
Relapsing Multiple Sclerosis
10/23
03/24
NCT06141473: Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Recruiting
3
1400
Europe, Canada, Japan, US, RoW
Frexalimab, Teriflunomide, Placebo infusion, Placebo tablet, MRI contrast-enhancing agents, Cholestyramine, Activated charcoal
Sanofi
Multiple Sclerosis
05/27
05/27
NCT06372145: A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

Recruiting
3
2500
US, RoW
Tolebrutinib, SAR442168, Placebo, Teriflunomide, Aubagio
Sanofi
Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
04/29
04/29
GEMINI 2, NCT04410991 / 2020-000644-55: Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)

Active, not recruiting
3
900
Europe, Canada, US, RoW
Tolebrutinib, SAR442168, Teriflunomide HMR1726, Placebo to match Tolebrutinib, Placebo to match Teriflunomide
Sanofi
Relapsing Multiple Sclerosis
08/24
08/24
GEMINI 1, NCT04410978: Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)

Hourglass Jan 2023 - Dec 2023 : Data from GEMINI 1 trial for multiple sclerosis
Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Tolebrutinib, SAR442168, Teriflunomide HMR1726, Placebo to match Tolebrutinib, Placebo to match Teriflunomide
Sanofi
Relapsing Multiple Sclerosis
08/24
08/24
STHENOS, NCT04788615 / 2020-004505-32: Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS

Recruiting
3
186
Europe
Ofatumumab, OMB157, First line DMT, Glatiramer acetate or Interferon or Peg-Interferon beta-1a or Teriflunomide or Dimethyl fumarate or Diroximel fumarate
Novartis Pharmaceuticals, Novartis Pharma AG
Multiple Sclerosis
10/25
01/26
FENhance, NCT04586010 / 2019-004857-10: A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Active, not recruiting
3
746
Europe, US, RoW
Fenebrutinib, Teriflunomide, Placebo
Hoffmann-La Roche
Relapsing Multiple Sclerosis
10/25
11/25
FENhance 2, NCT04586023 / 2020-001168-28: Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Active, not recruiting
3
751
Europe, Canada, US, RoW
Fenebrutinib, Teriflunomide, Placebo
Hoffmann-La Roche
Relapsing Multiple Sclerosis
10/25
11/25
REMODEL-2, NCT05156281 / 2020-005929-89: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, Canada, Japan, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
REMODEL-1, NCT05147220 / 2020-005899-36: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
MIST, NCT03133403 / 2012-004165-41: Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy

Recruiting
2/3
5
Europe
Tecfidera (BG12), Gilenya, fingolimod, Tysabri®, natalizumab, Avonex/Betaseron/Copaxone/Rebif, (Avonex®, Betaseron®, Copaxone®, Rebif®), Hematopoietic stem cell transplantation (HSCT)
Sheffield Teaching Hospitals NHS Foundation Trust
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
12/21
12/21
NCT04806737: Teriflunomide vs. Placebo During Gluten Challenge in Celiac Disease

Recruiting
2a
15
Europe
Teriflunomide Oral Tablet, Gluten challenge
Oslo University Hospital
Celiac Disease
08/22
08/22
NCT04056897: Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis

Active, not recruiting
2
270
RoW
BCD-132, 125 mg, Teriflunomide, Placebo, BCD-132, 500 mg
Biocad
Multiple Sclerosis
07/20
12/21
2020-002307-18: A study on the efficacy and tolerability of a 14-day treatment with teriflunomide 14 mg tablets vs. placebo in subjects with well-controlled coeliac disease undergoing a 3-day gluten challenge

Not yet recruiting
2
15
Europe
Aubagio, Capsule, Aubagio
Oslo University Hospital, Oslo University Hospital
Coeliac disease, Coeliac disease, Diseases [C] - Immune System Diseases [C20]
 
 
NCT06190145: Teriflunomide for Steroid-resistant/Relapse Immune Thrombocytopenia

Recruiting
2
40
RoW
Teriflunomide, AUBAGIO
Peking University People's Hospital
Immune Thrombocytopenia
10/24
06/25
NCT06176911: The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia

Recruiting
2
124
RoW
Teriflunomide, AUBAGIO, Danazol
Peking University People's Hospital, Beijing Luhe Hospital, Chinese PLA General Hospital, Navy General Hospital, Beijing, Beijing Hospital, Beijing Friendship Hospital, Peking University First Hospital, Peking University Third Hospital, China-Japan Friendship Hospital, Beijing Tsinghua Changgeng Hospital
Immune Thrombocytopenia
12/24
07/25
NCT06176235: Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia

Recruiting
2
132
RoW
Teriflunomide, AUBAGIO, Dexamethasone
Peking University People's Hospital, Beijing Luhe Hospital, Chinese PLA General Hospital, Navy General Hospital, Beijing, Beijing Hospital, Beijing Friendship Hospital, Peking University First Hospital, Peking University Third Hospital, China-Japan Friendship Hospital, Beijing Tsinghua Changgeng Hospital
Immune Thrombocytopenia
12/24
05/25
NCT04799288: Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis

Recruiting
1/2
24
US
Teriflunomide
National Institute of Neurological Disorders and Stroke (NINDS)
HAM/TSP
08/25
08/25
Clad'Action, NCT04821596: Study of the Mechanisms of Action of Cladribine in Multiple Sclerosis

Recruiting
N/A
75
Europe
biological collection
University Hospital, Rouen
Multiple Sclerosis
08/21
12/21
NCT05075499: Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab

Recruiting
N/A
70
RoW
COVID-19 vaccination, Blood withdrawn
Sheba Medical Center, Sanofi
Multiple Sclerosis
12/21
09/22
CPE, NCT05762003: Czech Pharmaco-epidemiological Study on Disease Modifying Drugs

Completed
N/A
17478
RoW
interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
IMPULS Endowment Fund
Multiple Sclerosis
12/21
12/21
NCT05811949: Effects of Dimethyl Fumarate on Cognitive Performance and Brain Abnormalities in Multiple Sclerosis.

Recruiting
N/A
52
Europe
Dimethyl Fumarate 240 MG [Tecfidera]
IRCCS Centro Neurolesi "Bonino-Pulejo"
Multiple Sclerosis
10/22
02/25
AUBACOG, NCT03768648: Cognition and MRI Markers in MS Patients With Aubagio® Treatment

Completed
N/A
75
Europe
Clinical assessment, Ecological evaluation, Neuropsychological evaluation, Psychological evaluation, MRI Evaluation
University Hospital, Bordeaux, Genzyme, a Sanofi Company
Multiple Sclerosis, Relapsing-Remitting
02/23
02/23
NCT03198351: An Observational Study on Teriflunomide-exposed Pregnancies

Completed
N/A
220
Canada, US
Teriflunomide (HMR1726), Aubagio
Sanofi
Multiple Sclerosis
06/23
06/23
DOT-MS, NCT04260711: Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis ().

Recruiting
N/A
130
Europe
DMT, Interferon, Glatiramer acetate, Dimethylfumarate, Teriflunomide
VU University Medical Center
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
08/23
01/24
TERIPET, NCT03368677: Effect of Teriflunomide Treatment on Microglial Activation in an MS Patient Cohort at Risk of Progression

Active, not recruiting
N/A
26
Europe
Turku University Hospital
Multiple Sclerosis
12/24
12/24
NCT03399981: Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries

Completed
N/A
80327
US
Tysabri, Natalizumab BG00002
Biogen
Progressive Multifocal Leukoencephalopathy
12/23
12/23
ULTIMS, NCT05718947: Ultra-high-field Brain MRI in Multiple Sclerosis

Active, not recruiting
N/A
10
Europe
Brain MRI (3T, 7T, 9.4T)
Zuyderland Medisch Centrum, Scannexus
Multiple Sclerosis
07/24
08/24
RESEPTOR 5-HT7, NCT05746845: Implication of 5-HT7 Receptor in Inflammatory Mechanisms in Multiple Sclerosis

Recruiting
N/A
120
Europe
Blood sample
Centre Hospitalier Régional d'Orléans
Healthy, Multiple Sclerosis
03/25
03/25
TREAT-MS, NCT03500328: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Recruiting
N/A
900
US
Natalizumab, Alemtuzumab, Ocrelizumab, Rituximab, Cladribine, Ofatumumab, Ublituximab-xiiy, Tysabri, Lemtrada, Ocrevus, Rituxan, Mavenclad, Kesimpta, Briumvi, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso
Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Multiple Sclerosis, Relapsing-Remitting
08/25
08/25
NCT05112484: Therapeutic Monitoring of Drugs Used in the Treatment of Multiple Sclerosis

Not yet recruiting
N/A
600
RoW
Measurement of concentrations of orally-used DMDs, Genetic testing, Parameters for routine use of DMDs, Side effects of orally used DMDs
University Hospital Ostrava, University of Ostrava
Multiple Sclerosis
11/25
05/26
STATURE, NCT04676204: Relationship Between Oral DMT Burden and Adherence in MS

Enrolling by invitation
N/A
323
RoW
Cladribine, Mavenclad, Dimethyl fumarate, Tecfidera, Fingolimod, Gilenya, Teriflunomide, Aubagio, Ozanimod, Zeposia, Diroximel fumarate, Vumerity
Monash University
Multiple Sclerosis, Adherence, Medication
11/25
07/26
KRONOS, NCT05776888: Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years

Recruiting
N/A
100
Europe
Ofatumumab
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
08/26
08/26
PROMISE, NCT05962177: Montpellier PROspective Cohort in Relapsing Remitting Multiple Sclerosis Using Imaging and Serologic

Recruiting
N/A
400
Europe
Magnetic Resonance Imaging, Blood withdrawal, Neuropsychological tests
University Hospital, Montpellier
Multiple Sclerosis
07/28
07/28
NCT05767736: A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)

Not yet recruiting
N/A
10500
NA
Diroximel Fumarate, VUMERITY, BIIB098, Dimethyl Fumarate, Tecfidera, DMF, BG00012, Disease-Modifying Therapies (DMTs)
Biogen
Multiple Sclerosis
12/32
12/32
GEMINI1, NCT04964791: RMS Study of BTK Inhibitor SAR442168

Recruiting
N/A
900
RoW
SAR442168
Peking University Third Hospital
Relapsing Multiple Sclerosis
08/21
08/24
DATE-TCM, NCT05415579: Demyelinating Diseases of the Central Nervous System Registry for Patients With Traditional Chinese Medicine

Not yet recruiting
N/A
2000
NA
Traditional Chinese medicine (TCM)
Dongzhimen Hospital, Beijing
Demyelinating Diseases of the Central Nervous System (DDC)
10/29
05/30

Download Options